SAN FRANCISCO — An impromptu survey at the American Society of Clinical Oncology’s recent Breast Cancer Symposium showed strong support for using new drugs early, based on pathological complete response data as a surrogate for survival.
Held from Sept. 7-9 in San Francisco, the symposium drew over 930 attendees. Prospects for using new drugs soon after diagnosis as neoadjuvant therapy – meaning prior to surgery –...